TY - JOUR
T1 - Automated Expansion of Primary Human T Cells in Scalable and Cell-Friendly Hydrogel Microtubes for Adoptive Immunotherapy
AU - Lin, Haishuang
AU - Li, Qiang
AU - Wang, Ou
AU - Rauch, Jack
AU - Harm, Braden
AU - Viljoen, Hendrik J.
AU - Zhang, Chi
AU - Van Wyk, Erika
AU - Zhang, Chi
AU - Lei, Yuguo
N1 - Funding Information:
H.L. and Q.L. contributed equally to this work. Leonard Akert at the Department of Chemical and Biomolecular Engineering at University of Nebraska, Lincoln assisted Q.L. with building the extruders. Aaron Howell at the Department of Chemical and Biomolecular Engineering at University of Nebraska, Lincoln drew the 3D graphics. Flow cytometry was done in the Morrison center, the Flow Cytometry core, University of Nebraska, Lincoln with the assistance of Dirk Anderson. The University of Nebraska has filed a patent application related to the technology described in this work to the United States Patent and Trademark Office.
Publisher Copyright:
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2018/8/8
Y1 - 2018/8/8
N2 - Adoptive immunotherapy is a highly effective strategy for treating many human cancers, such as melanoma, cervical cancer, lymphoma, and leukemia. Here, a novel cell culture technology is reported for expanding primary human T cells for adoptive immunotherapy. T cells are suspended and cultured in microscale alginate hydrogel tubes (AlgTubes) that are suspended in the cell culture medium in a culture vessel. The hydrogel tubes protect cells from hydrodynamic stresses and confine the cell mass less than 400 µm (in radial diameter) to ensure efficient mass transport, creating a cell-friendly microenvironment for growing T cells. This system is simple, scalable, highly efficient, defined, cost-effective, and compatible with current good manufacturing practices. Under optimized culture conditions, the AlgTubes enable culturing T cells with high cell viability, low DNA damage, high growth rate (≈320-fold expansion over 14 days), high purity (≈98% CD3+), and high yield (≈3.2 × 108 cells mL−1 hydrogel). All offer considerable advantages compared to current T cell culturing approaches. This new culture technology can significantly reduce the culture volume, time, and cost, while increasing the production.
AB - Adoptive immunotherapy is a highly effective strategy for treating many human cancers, such as melanoma, cervical cancer, lymphoma, and leukemia. Here, a novel cell culture technology is reported for expanding primary human T cells for adoptive immunotherapy. T cells are suspended and cultured in microscale alginate hydrogel tubes (AlgTubes) that are suspended in the cell culture medium in a culture vessel. The hydrogel tubes protect cells from hydrodynamic stresses and confine the cell mass less than 400 µm (in radial diameter) to ensure efficient mass transport, creating a cell-friendly microenvironment for growing T cells. This system is simple, scalable, highly efficient, defined, cost-effective, and compatible with current good manufacturing practices. Under optimized culture conditions, the AlgTubes enable culturing T cells with high cell viability, low DNA damage, high growth rate (≈320-fold expansion over 14 days), high purity (≈98% CD3+), and high yield (≈3.2 × 108 cells mL−1 hydrogel). All offer considerable advantages compared to current T cell culturing approaches. This new culture technology can significantly reduce the culture volume, time, and cost, while increasing the production.
UR - http://www.scopus.com/inward/record.url?scp=85046813730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046813730&partnerID=8YFLogxK
U2 - 10.1002/adhm.201701297
DO - 10.1002/adhm.201701297
M3 - Article
C2 - 29749707
AN - SCOPUS:85046813730
SN - 2192-2640
VL - 7
JO - Advanced Healthcare Materials
JF - Advanced Healthcare Materials
IS - 15
M1 - 1701297
ER -